In a nutshell This study investigated the effect of tandem stem cell transplantation (SCT) in patients with high-risk relapsed/refractory Hodgkin Lymphoma (HL). The main finding was that patients treated with tandem SCT had greater progression-free survival than those without. Some background A SCT involves the transfer of stem cells into the patient to...
Read MoreIn a nutshell This article reviewed the results of new targeted immunotherapy treatments in patients with classical Hodgkin’s lymphoma that is relapsed or refractory (does not respond to treatment). Some background Thanks to treatment advances, classical Hodgkin’s lymphoma (cHL) has become one of the most curable cancers. Frontline ABVD...
Read More
In a nutshell This study reviewed the medical records of patients with nodular lymphocytic predominant Hodgkin's lymphoma (NLPHL) to evaluate their outcomes. This study concluded that all patients had excellent outcomes, even with a wide range of therapies. Some background Nodular lymphocytic predominant Hodgkin's lymphoma (NLPHL) is an...
Read More
In a nutshell This study compared the long-term outcomes of Hodgkin’s lymphoma (HL) patients who received plerixafor (Mozobil) to those who did not prior to autologous stem cell transplantation (autoSCT). This study concluded that plerixafor-treated patients had similar outcomes as patients who received conventional regimens. Some background...
Read More
In a nutshell This study investigated the outcomes of primary refractory or relapsed Hodgkin’s lymphoma (HL) patients who received GBM (gemcitabine, busulfan, melphalan) or BEAM (carmustine, etoposide, cytarabine, melphalan) chemotherapy before autoSCT (autologous stem cell transplantation). This study concluded that GBM improved patient outcomes...
Read More
In a nutshell This study analyzed the survival outcomes of Hodgkin’s lymphoma (HL) patients who experience treatment failure after high-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (autoSCT). This study concluded that a second stem cell transplant with or without brentuximab vedotin (Adcetris) may lead to better...
Read More
In a nutshell This study analyzed data from patients with Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphoma (NHL) who received TECAM (etoposide, thiotepa, cytarabine, cyclophosphamide, melphalan) chemotherapy before autoSCT (autologous stem cell transplantation). The authors concluded that TECAM is an effective pre-autoSCT regimen for...
Read More
In a nutshell This study investigated the impact of white blood cell counts on the outcomes of newly diagnosed Hodgkin’s lymphoma (HL) patients receiving treatment mediated by PET2 (PET scanning after 2 cycles of chemotherapy). This study concluded that ratios of different types of white blood cells combined with PET2 can be a meaningful...
Read MoreIn a nutshell This study investigated the outcomes of classical Hodgkin’s lymphoma (cHL) patients who did or did not receive brentuximab vedotin (Adcetris) before allogeneic stem cell transplantation. This study concluded that pre-transplant brentuximab vedotin treatment does not lead to better post-transplant outcomes. Some background...
Read More
The adrenal glands-which are also called suprarenal glands-are part of the endocrine system and are found on the top of each kidney. How the endocrine system hormones work Hormones secreted from glands of the endocrine system travel in the bloodstream to target cells. Target cells have receptors that are specific to each hormone. The hormones and receptors...
Read More
In a nutshell This study examined the long-term safety and effectiveness of bendamustine (Treanda) in lymphoma and leukemia. This study concluded that bendamustine is a safe and effective therapy for these patients. Some background Bendamustine has been shown to have high effectiveness and few side effects for a wide range of lymphomas. This drug is...
Read More
In a nutshell This study looked at the effectiveness of treating elderly lymphoma patients with autologous stem cell transplantation. The study concluded that autologous stem cell transplantation should be considered on an individual basis, and age should not automatically disqualify elderly patients. Some background Patients with lymphoma...
Read More
